The problem with glycopeptides

被引:29
作者
Gould, I. M. [1 ]
机构
[1] Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland
关键词
D O I
10.1016/j.ijantimicag.2007.03.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:1 / 3
页数:3
相关论文
共 36 条
[1]  
[Anonymous], 46 INT C ANT AG CHEM
[2]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[3]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[4]   Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].
Charles, PGP ;
Ward, PB ;
Johnson, PDR ;
Howden, BP ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451
[5]   Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus [J].
Charlesworth, R. ;
Warner, M. ;
Livermore, D. M. ;
Wilson, A. P. R. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (01) :186-189
[6]  
*CLIN LAB STAND I, 2006, M100S16 CLSI
[7]  
DAVEY PG, 1991, J ANTIMICROB CHEM SB, V27, P51
[8]   PROTEIN-BINDING AND SERUM BACTERICIDAL ACTIVITIES OF VANCOMYCIN AND TEICOPLANIN [J].
DYKHUIZEN, RS ;
HARVEY, G ;
STEPHENSON, N ;
NATHWANI, D ;
GOULD, IM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1842-1847
[9]   STAPHYLOCOCCUS-AUREUS ENDOCARDITIS - COMBINED THERAPY WITH VANCOMYCIN AND RIFAMPIN [J].
FAVILLE, RJ ;
ZASKE, DE ;
KAPLAN, EL ;
CROSSLEY, K ;
SABATH, LD ;
QUIE, PG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (18) :1963-1965
[10]   A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital [J].
Garnier, F ;
Chainier, D ;
Walsh, T ;
Karlsson, A ;
Bolmström, A ;
Grelaud, C ;
Mounier, M ;
Denis, F ;
Ploy, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (01) :146-149